Fluoxetine in the treatment of Huntington’s disease
The DOI matches its Crossref record.
Abstract
Rationale Recent reports suggest the possible efficacy of selective serotonin reuptake inhibitors (SSRIs) in treating particular symptoms of Huntington's disease (HD), such as aggressiveness and agitation. However, predictive features to identify HD subjects who may benefit from this treatment have not been established. Objectives Two individuals from a large HD pedigree with a very high prevalence of obsessive-compulsive disorder (OCD) have been treated with fluoxetine, an SSRI. We aimed at testing whether the co-occurrence of the two disorders in this pedigree might have some underlying pathogenic similarities, maybe also resulting in a good response of HD symptoms to the anti-obsessional drug fluoxetine. Methods Each patient was evaluated, started on fluoxetine treatment, and then reassessed monthly with: (a) the HD motor rating scale, to rate the impairment of movement, and (b) the mini mental state examination, for a cognitive ascertainment. They had a complete psychiatric and neurologic examination as well. Results Both subjects showed an excellent response to fluoxetine. One patient exhibited improvement of the motor and behavioral components of the disorder, while the other improved also in the cognitive domain of HD. The best response was shown by the individual suffering from OCD in her youth. The amelioration in these two patients has been maintained for 2 and 6 years, respectively, whereas the course of HD is that of a progressive deterioration. Conclusions Firm c…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In patients, a study shows that fluoxetine may prevent progression of the disease (De Marchi et al., 2001), while another did not find conclusive evidence (Moulton et al., 2014).”
From Depression and adult neurogenesis: Positive effects of the antidepressant fluoxetine and of physical exercise (2018) · cites this paper as De Marchi et al., 2001
Citations
Cites
Still being checked.
Cited by
Carroll, J. B., Warby, S. C., Southwell, A. L., Doty, C. N., Greenlee, S., Skotte, N., Hung, G., Bennett, C. F., Freier, S. M., & Hayden, M. R. (2011) · Molecular Therapy · doi:10.1038/mt.2011.201 · Cited by 293
Micheli, L., Ceccarelli, M., D’Andrea, G., & Tirone, F. (2018) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2018.09.002 · Cited by 288
Results of the citalopram to enhance cognition in Huntington disease trial
Beglinger, L. J., Adams, W. H., Langbehn, D., Fiedorowicz, J. G., Jorge, R., Biglan, K., Caviness, J., Olson, B., Robinson, R. G., Kieburtz, K., et al. (2014) · Movement Disorders · doi:10.1002/mds.25750 · Cited by 65
Metadata
- Authors
- De Marchi, N., Daniele, F., & Ragone, M. A.
- Affiliations
- University of Campania "Luigi Vanvitelli" (IT)
- Venue
- Psychopharmacology
- Published
- 2001-01-09
- Volume
- 153
- Issue
- 2
- Pages
- 264-266
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W2015224507
- Cited by
- 57
- References
- 0
- Citations by year
- 2025: 2 · 2024: 1 · 2023: 2 · 2022: 2 · 2021: 2 · 2020: 1 · 2019: 2 · 2018: 3 · 2017: 3 · 2016: 3 · 2014: 1 · 2013: 1 · 2012: 6
- FWCI
- 0.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
- Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Keywords
- Huntington's disease, fluoxetine, selective serotonin reuptake inhibitors, obsessive-compulsive disorder, serotonergic system, motor symptoms, cognitive function, behavioral symptoms, agitation, treatment response
- MeSH terms
- Affect, Aggression, Cognition Disorders, Female, Fluoxetine, Humans, Huntington Disease, Middle Aged, Obsessive-Compulsive Disorder, Disease Progression, Antidepressive Agents, Second-Generation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fluoxetine in the treatment of Huntington’s disease. https://app.cochat.ai/papers/10.1007/s002130000575
- The paper
- De Marchi, N., Daniele, F., & Ragone, M. A. (2001). Fluoxetine in the treatment of Huntington’s disease. Psychopharmacology. https://doi.org/10.1007/s002130000575
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.